In this episode, I sit down with my friend, CEO of Genialis, and Co-founder, Board Director & Executive Committee Member of the Alliance for Artificial Intelligence in Healthcare, Rafael Rosengarten.

To find more about Rafael, find him on Linkedin, genialis.com, or at theaaih.org.

Episode is available on Apple Podcasts, Spotify, and Youtube. 

Dylan Reid
Youtube:AIHealthcarePodcast
X:@AIHealthcarePod
Linkedin: The AI Healthcare Report

In this episode, I sit down with Generative AI Consultant, Chapter President to the Kansas City Generative AI Committee for the VR/AR Association, and an advisory board member to the University of Kansas School of Nursing; my friend Doug Hohulin.

To find more about Doug, find him on Linkedin.

Episode is available on Apple Podcasts, Spotify, and Youtube. 

Dylan Reid
Youtube:AIHealthcarePodcast
X:@AIHealthcarePod
Linkedin: The AI Healthcare Report

In this episode, I sit down with AI Entrepreneur and friend Peter Skuta on his invention the "AI Child" and how the "AI Child" can be used to increase health outcomes domestically and globally.

To find more about Peter, find him on Linkedin. 

Episode is available on Apple Podcasts, Spotify, and Youtube. 

What is Medical Affairs? Medical Affairs Expert Luisa Scott educates us on the field and why is it a crucial component of health care operations.

To learn more about Luisa, find her on Linkedin here:  https://www.linkedin.com/in/luisa-scott-phd/ 

Key takeaways:

1. Medical Affairs can be divided into two elements, which are the following:

i. Field Medical Team-tasked with providing non-promotional materials to healthcare providers and digging into the respective data.

ii. Post-market data collection- which patients are benefitting from the medical product?

2. One struggle that medical affairs professionals have faced among key health care stakeholders is how the utilization of medical products impacts the commercial strategies of companies. 

3. One of the values that Medical Affairs brings to the organization is the ability for the field to analyze, and crunch data to make it more accessible to consumers in real-time.

How do we showcase cities, such as those of Baton Rouge, Louisiana maintain a key importance in the role of A.I. technology implementation in healthcare in the United States? Adjunct Instructor at Louisiana State University in Baton Rouge, Co-Founder of Disrupt Ready, Henry Hays, educates us on the progress, but also what is still needed to make cities in the South, such as Baton Rouge ready for the future.

To find out more about Henry, please find him on LinkedIn here:  https://www.linkedin.com/in/henryhays/ 

Key takeaways:
1. The A.I. economy in southern cities, such as Baton Rouge is still in its early stages. 

2. Southern businesses that understand what is and is not A.I. and then implement it will be the ones that survive in the future.

3. LSU is leading the way in A.I. education by constructing classes that allow students to learn, and build large language models that solve problems for businesses, which can lead to full-time employment for students.

How do we expedite the drug approval process in the United States? Co-Founder & CEO of EVQLV, Andrew Satz, educates us on how and what is needed to do so. 

To find out more about Andrew, please find him on LinkedIn here: https://www.linkedin.com/in/andrewsatz/

To find out more about EVQLV, please find the company website here: https://evqlv.com/

Key takeaways:

1. The acceleration of getting drugs to patients by decreasing costs for researchers, industry, and other key stakeholders motivates EVQLV.

2. A.I. will cause hyper-specialization, which will make doctors become more productive. 

3. Making data more accessible through government agencies and investing at a governmental level will drive future A.I.  models and specialized medicines for populations.

What is brain health? CEO + Co-Founder of DigiCARE Realized and Global Consortium Member of Social Impact Partners educates us on why brain health is crucial in pushing healthcare forward in the United States.

To connect with Brittany please find her Linkedin here. 

Key takeaways:

1.Being intentional for treatments and cures are needed to make the necessary advancements for brain health so that families or those impacted have access to the resources that they need. 

2. Having an understanding of the pathology of diseases, such as Alzheimer's can provide clinicians with more personalized, effective treatment plans.

3.Shifting from being reactive to proactive is essential to understanding brain health.

Have you ever been curious about learning about navigating the U.S. Healthcare System from the perspective of an immigrant? In this interview, I sit down with my friend and COO of BeKey, Alex Koshykov on his story on navigating healthcare in the United States and its differences to his home country of Ukraine.

Connect with Alex here. 

Be sure to read his newsletter US Healthcare, which can be found on his Linkedin!

What does the future of A.I. in healthcare look like in Australia? Where are the potential challenges and opportunities for implementing A.I. technology in the country? Come learn from Australia A.I. Healthcare expert and Founder of NurseFusion, Sarah Hughes, as we uncover these questions. We had to switch to Zoom because of some technical difficulties. 

Linkedin:   / sarahhughesleadingchange 

Nursefusion Website: https://nursefusion.com.au/

Cover/Episode Art made by Daniel Maley with Dall-E

Where are EU regulations headed when it comes to A.I. in healthcare? With his expertise in the Italian market in pharmaceutical marketing and sales, Manuel Mitola, MBA Mitola teaches us how A.I. is being adopted and used in Europe. He also educates us on key legislative priorities while also balancing innovation on the European continent.

Key takeaways:

1. Each Italian state has slightly different rules in the marketing of pharmaceuticals depending on the region.

2. GDPR does not explicitly mention A.I. because the regulation came into being before A.I. was broadly known and the law is vague on prescriptions.

3. Pharmaceutical companies in Europe are risk adverse in Europe and interpret GRPR in the most conservative manner, which means applying a limitation on the usage of data.

The A.I. Healthcare Podcast is now part of the Forest Hill Labs Family.

Sign up at www.foresthilllabs.net to get Forest Hill Labs: A Health Market Intelligence, Policy, and Thought Leadership Consultancy content!